UnitedHealth Group Incorporated (UNH) Outlook Strong, Analysts Watch Closely

Group 1 - UnitedHealth Group Incorporated (NYSE:UNH) is receiving positive attention from analysts, with a consensus 1-year median price target of $410, indicating a potential upside of 28% [1] - Wells Fargo analyst Stephen Baxter reaffirmed a Buy rating on UnitedHealth with a price target of $400, while a Barclays analyst maintained a Buy rating with a price target of $386 [1] - The company announced the addition of Scott Gottlieb, former FDA commissioner, to its board, effective immediately [2] Group 2 - Scott Gottlieb is recognized for his public health advocacy, particularly in reducing flavored e-cigarette use among youths, and has experience in enhancing competition through expedited approvals [3] - UnitedHealth operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx, and is committed to improving the healthcare system since its founding in 1974 [4]